Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011-20
Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011-20
复制标题
DOI：
10.1377/hlthaff.2015.1086
复制
发表时间：
2016-02-01
期刊：
影响因子：
9.7
通讯作者：
Walker, Damian G.
中科院分区：
文献类型：
--
作者：
Ozawa, Sachiko;Clark, Samantha;Walker, Damian G.
对投资回报的分析可以帮助决策者支持、优化和倡导在世界上最贫穷国家扩大免疫规划。我们评估了2011- 2020年“疫苗十年”期间，94个中低收入国家为预防与10种抗原相关的疾病而接种疫苗的预期覆盖率水平的投资回报。我们通过使用疫苗、供应链和服务提供的成本及其相关的经济效益得出这些估计。根据避免疾病的成本，我们估计，预计免疫接种将产生比十年成本高16倍的净回报（不确定性范围：10-25）。使用全收入方法，即量化人们对更长寿和更健康生活的价值，我们发现净回报是成本的44倍（不确定性范围：27-67）。在所有抗原中，净收益大于成本。但要实现免疫规划投资的实质性正回报，政府和捐助者必须提供必要的投资。
An analysis of return on investment can help policy makers support, optimize, and advocate for the expansion of immunization programs in the world's poorest countries. We assessed the return on investment associated with achieving projected coverage levels for vaccinations to prevent diseases related to ten antigens in ninety-four low-and middle-income countries during 2011-20, the Decade of Vaccines. We derived these estimates by using costs of vaccines, supply chains, and service delivery and their associated economic benefits. Based on the costs of illnesses averted, we estimated that projected immunizations will yield a net return about 16 times greater than costs over the decade (uncertainty range: 10-25). Using a full-income approach, which quantifies the value that people place on living longer and healthier lives, we found that net returns amounted to 44 times the costs (uncertainty range: 27-67). Across all antigens, net returns were greater than costs. But to realize the substantial positive return on investment from immunization programs, it is essential that governments and donors provide the requisite investments.